The Preemptive Analgesic Efficacy of Nefopam

Seoul National University

Status: Completed

Conditions: Breast Neoplasm

Treatments: Drug: Nefopam; Drug: Saline

Study type: Interventional

Funder types: Other

Identifiers

NCT02561468

Nefo_breast cancer

Details and patient eligibility

About

Nefopam is administered as a preemptive analgesic drug to the patient undergoing breast cancer surgery. It will be evaluated whether postoperative acute and chronic pain can be reduced.

Enrollment: 94 patients

Sex: Female

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with breast cancer
• Lumpectomy with axillary lymph node dissection or Lumpectomy with sentinel lymph node biopsy
• American Society of Anesthesiologists physical status I or II

Exclusion criteria

• Refusal
• Seizure
• Cardiac disease
• Monoamine oxidase inhibitor user
• Urologic disease
• Glucoma
• Preoperative analgesic drug medication
• Pregnancy
• Recurred breast cancer patient

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

94 participants in 2 patient groups, including a placebo group

Nefopam

Experimental group

Description:

20 mg nefopam in 100 ml normal saline is infused before starting operation.

Treatment:

Drug: Nefopam

Control

Placebo Comparator group

Description:

100 ml normal saline is infused before starting operation.

Treatment:

Drug: Saline